FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Tuesday

 

Lemtrada Seen to Help Reverse MS Disability in People in Earlier Stages of Disease




























Lemtrada (alemtuzumab) was seen to help reverse disability among patients with relapsing forms of MS in relatively early stages of the disease, researchers report.

The study, “Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients,” published in the journal Neurology, supports the idea that treatment with Lemtrada should be considered earlier in disease management, particularly since its benefits seem likely outnumber its side effects.

“While many MS drugs slow the progress of disability, there have been little data about the ability of treatments to help restore function previously lost due to MS,” Gavin Giovannoni, the study’s first author and a professor at the Blizard Institute, Queen Mary University of London, said in a news release.

“We saw improvements in many of our participants who received alemtuzumab treatment, including their mobility, coordination, bladder function and thinking skills,” he said.

The Phase 3 CARE-MS II trial (NCT00548405) compared Lemtrada and Rebif (interferon beta-1a) in patients who previously had continuing relapses while being treated with other drugs. In total, 426 patients were treated with Lemtrada, and 202 with Rebif. Patients received treatment every three months, and functional tests were performed at the same intervals. Lab tests were done on a monthly basis.

Researchers evaluated patients’ performance in a series of functional tests, comparing abilities at the beginning and end of the study, which ran for two years.

Lemtrada-treated patients were found to be more likely to improve their Expanded Disability Status Scale (EDSS) scores, and at the end of the study, nearly 28 percent had improved by at least one point on the disability scale. The proportion of patients who improved while receiving Rebif, in comparison, was 15 percent.

Those receiving Lemtrada were also 2.5 times more likely to improve their cognitive skills, and had more than two times a greater likelihood of reduced ataxia (lack of voluntary coordination of muscle movements) compared to Rebif-treated patients.

Giovannoni, however, underscored that the treatment was only able to reverse disability in patients who were in a relatively early stage in the disease course. Other studies are needed to determine if the same is true for people in more advanced MS stages.

“These benefits have to be weighed against the drug’s risks, which include serious, and rarely, life-threatening, autoimmune problems, as well as infusion reactions and infections,” Giovannoni said.

Story Source: The above story is based on materials provided by MULTIPLESCLEROSISNEWSTODAY
Note: Materials may be edited for content and length

Labels:



Go to Newer News Go to Older News